Viewing nowUnival 160 mg (Valsartan)
Valsartan 160mg
Tablet · Prescription medication
Hanil Pharmaceutical Co., Ltd.

MFDS item code 200809240 · Notified 2008.09.04 · Insurance code 657201290
Treatment of essential hypertension and heart failure; reduction in the risk of death after myocardial infarction
This medication is used for the treatment of essential hypertension. It is also effective in some heart failure patients who are intolerant to ACE inhibitors, especially those with NYHA classes II to IV. It is used to reduce the risk of mortality in patients with left ventricular dysfunction after a myocardial infarction. In summary, it is used for hypertension, certain heart failure, and reducing the risk of death post-myocardial infarction.
(Tablets) * 40, 80, 160 mg 1. Essential hypertension Take with water during a meal or between meals. It is recommended to take the medicine at the same time each day (e.g., in the morning), if possible. 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be coadministered. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Elderly patients (aged 75 years and older): Initiate treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily; do not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily. Thereafter, over several weeks, increase the dose as tolerated by the patient to 40 mg, 80 mg, and 160 mg per dose, administered twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary when creatinine clearance is 10 mL/min or higher. However, do not administer this medicine to patients with creatinine clearance below 10 mL/min or to patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, it is preferable not to exceed a daily dose of 80 mg. If administering 80 mg or more daily, consider whether the benefits of dose escalation outweigh the risks. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age. The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age.
This medication can cause serious harm to the fetus, especially during the second and third trimesters of pregnancy, and should never be taken during pregnancy. It should be discontinued immediately if pregnancy is confirmed. Individuals allergic to this medication or any of its components, pregnant or breastfeeding women, and patients with severe liver or kidney diseases should not use it. Additionally, patients genetically unable to digest lactose should avoid this medication. Elderly patients, those with hyperkalemia, hepatic impairment, and patients with valvular heart disease or cardiovascular diseases should use it with caution. Heart failure patients or those who have had a myocardial infarction must closely monitor renal function, and if blood pressure drops too low, immediate consultation with a healthcare professional is necessary. This medication lowers blood pressure, and thus, when first taken, can cause dizziness or fainting due to sudden blood pressure drops, so care should be taken. Patients undergoing dialysis or on sodium restriction, as well as those taking diuretics, may experience hypotension risks and should increase the dose gradually while monitoring their condition. During treatment with this medication, potassium levels may rise, so extra caution is needed when taking it with potassium-sparing diuretics or potassium supplements. Co-administration with non-steroidal anti-inflammatory drugs may reduce blood pressure-lowering effects or worsen kidney function, so kidney function should be monitored regularly. If taken with lithium preparations, there may be an increase in serum lithium levels leading to toxicity, so monitoring is also necessary in this case. This medication has not been established for the safety and efficacy in children and adolescents and should not be used in these populations. In cases of overdose, there is a risk of severe hypotension and decreased consciousness, so immediate emergency treatment is required, and dialysis is ineffective. Store in a place out of reach of children and do not transfer to another container.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. It is also important to keep it at a cool place below 30 degrees Celsius to maintain its efficacy.
Orange oval film-coated tablet with a grayish tint
100 tablets (10 tablets/PTP × 10)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowValsartan 160mg
Tablet · Prescription medication
Hanil Pharmaceutical Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.